It has been proposed that prostaglandin E 2 (PGE 2 ) is released from astrocytic endfeet to dilate parenchymal arterioles through activation of prostanoid (EP 4 ) receptors during neurovascular coupling. However, the direct effects of PGE 2 on isolated parenchymal arterioles have not been tested. Here, we examined the effects of PGE 2 on the diameter of isolated pressurized parenchymal arterioles from rat and mouse brain. Contrary to the prevailing assumption, we found that PGE 2 (0.1, 1, and 5 mmol/L) constricted rather than dilated parenchymal arterioles. Vasoconstriction to PGE 2 was prevented by inhibitors of EP 1 receptors. These results strongly argue against a direct role of PGE 2 on arterioles during neurovascular coupling.
INTRODUCTION
Local blood flow is regulated by neuronal activity so as to match changes in the metabolic demand of brain tissue with the supply of oxygen and glucose, a process that is critical to maintain cerebral homeostasis and to prevent the development of ischemic conditions. This linkage between neuronal activity and cerebral blood flow, termed as neurovascular coupling or functional hyperemia, 1 is rapid (seconds) and occurs at the level of the cerebral microcirculation within the brain parenchyma. Local increases in cerebral blood flow are mediated by dilation of parenchymal arterioles, 2 which, unlike surface cerebral arteries (pial arteries), are encased by astrocytic processes ('endfeet'). 1 Recent evidence indicates that information about neuronal activity is communicated to (1) surface arterioles via astrocytic processes comprising the glia limitans and to (2) parenchymal arterioles through elevation of astrocytic Ca 2 þ and the subsequent engagement of Ca 2 þ -dependent vasodilatory pathways in astrocytic endfeet. 1, 3 Two potential Ca 2 þ -dependent astrocytic endfoot targets in particular have received considerable research attention: large-conductance, Ca 2 þ -sensitive K þ (BK) channels, which deliver K þ into the restricted perivascular space and dilate vessels by activating strong inwardly rectifying K þ channels, [4] [5] [6] and phospholipase A 2 , 3, 7 which produces arachidonic acid through the hydrolysis of membrane lipids. Prostaglandin E2 (PGE 2 ), a metabolite of arachidonic acid produced by the action of cyclooxygenase (COX), has been proposed as a major mediator of neurovascular coupling. 8 A role for PGE 2 in neurovascular coupling has largely been inferred from studies on the effects of COX inhibitors on neurally evoked vasodilation in brain slices. 8 However, some studies have found no effect of COX inhibition on neurovascular coupling in brain slices, 6 and others have attributed the reduction of functional hyperemia by COX inhibition to effects on COX2 in neurons. 9 Moreover, whether COX is even expressed in astrocytes has been called into question. 10 In theory, PGE 2 could act as a vasodilator or constrictor depending on the nature of the member of the G proteincoupled prostanoid (EP) receptor family. The G s -coupled EP 4 receptor signals through the cyclic adenosine monophosphatedependent protein kinase (PKA) pathway, which is associated with dilation. Whereas the EP 1 subtype is thought to couple to G q -type a subunits and mediates an increase in intracellular Ca 2 þ , consistent with a role in constriction. EP 3 , a subtype with promiscuous G protein-coupling propensity, has also been linked to elevation of intracellular Ca 2 þ and thus might mediate a contractile response to PGE 2 .
A critical test for the potential involvement of PGE 2 in neurovascular coupling is the demonstration that PGE 2 directly dilates isolated parenchymal arterioles. This evidence is currently lacking. In contrast, external K þ , also posited as a mediator of neurovascular coupling, has been shown to be a potent, rapid, reversible dilator of parenchymal arterioles. [4] [5] [6] Here, we tested the effects of PGE 2 on the diameter of isolated pressurized parenchymal arterioles from rat and mouse brain. Contrary to expectation, we found that PGE 2 constricted rather than dilated parenchymal arterioles.
MATERIALS AND METHODS Animals
All experimental protocols used in this study were in accord with institutional guidelines approved by the Institutional Animal Care and Use Committee of the University of Vermont. Male C57BL6 mice and male Sprague-Dawley rats were used. Animals (aged 3 to 4 months) were euthanized by intraperitoneal injection of sodium pentobarbital (mouse: 100 mg/kg; rat: 150 mg/kg) followed by rapid decapitation.
Pressurized Parenchymal Arterioles
After euthanasia, the brain was removed and placed into 41C MOPS-buffered saline. Parenchymal arterioles, arising from the M1 region of the middle cerebral artery and perfusing the neocortex, were dissected. Precapillary arteriolar segments were then cannulated on glass micropipettes with one end occluded in an organ chamber (University of Vermont Instrumentation and Model Facility) and pressurized using an arteriograph system (Living Systems Instrumentation, Inc., Burlington, VT, USA). Parenchymal arterioles were pressurized to 40 mm Hg and superfused (4 mL/min) with prewarmed (351C to 371C), gassed (5% CO 2 , 20% O 2 , 75% N 2 ) artificial cerebrospinal fluid (aCSF) for at least 1 hour. Only viable parenchymal arterioles, defined as those that developed pressure-induced myogenic tone greater than 20%, were used in subsequent experiments (Supplementary Figure 1A) . The average percentage of tone was 36.6 ± 3.4% (n ¼ 20) and 38.1 ± 2.3% (n ¼ 23) in parenchymal arterioles from rat and mouse, respectively. Endothelial function was tested by assessing the vasodilator response to NS309 (1 mmol/ L), an activator of endothelial small-(SK) and intermediate (IK)-conductance Ca 2 þ -activated K þ channels. Drugs were applied by addition to the superfusate. Vessel internal diameter was continuously monitored using a CCD camera and edge-detection software (IonOptix, Milton, MA, USA). Maximal dilation was obtained in nominally Ca 2 þ -free aCSF (0 mmol/L [Ca 2 þ ] o , 5 mmol/L EGTA).
Solutions
The composition of MOPS-buffered saline (in mmol/L) was 135 NaCl, 5 KCl, 1 KH 2 PO 4 , 1 MgSO 4 , 2.5 CaCl 2 , 5 D-glucose, 3 MOPS, 0.02 EDTA, 2 pyruvate, bovine serum albumin (10 mg/mL), pH 7.3 at 41C. The composition of aCSF (in mmol/L) was 125 NaCl, 3 KCl, 26 NaHCO 3 , 1.25 NaH 2 PO 4 , 1 MgCl 2 , 4 D-glucose, 2 CaCl 2 ; pH was 7.3 when aerated with 5% CO 2 .
Drugs
Stock solutions of PGE 2 (10 mmol/L in dimethyl sulfoxide) were prepared from powder each day of the experiment or stored at À 201C for o1 month, and were protected from exposure to light in accordance with recommendations of the suppliers. During experiments, PGE 2 was superfused immediately after dissolution in aCSF or dilution from dimethyl sulfoxide stock solutions to prevent PGA 2 formation from PGE 2 dehydration.
Prostaglandin E 2 was purchased from different suppliers (Enzo Life Sciences, Farmingdale, NY, USA; Sigma-Aldrich, St Louis, MO, USA; and Tocris Bioscience, Ellisville, MO, USA). No significant differences were observed among the responses to PGE 2 from the different vendors in parenchymal arteriolar diameter recording experiments. Prostacyclin (PGI 2 ) was purchased from Enzo Life Sciences. ZM241385 and SC51322 were purchased from Tocris Bioscience. AH6809 and adenosine were purchased from Sigma-Aldrich.
Data Analysis and Statistics
Changes in arteriolar diameter were calculated as percent change from baseline (change in diameter/initial diameter). Data are expressed as means±SEMs. Differences between two groups were analyzed using Student's t-test. Statistical significance was tested at the 95% (Po0.05) confidence level.
RESULTS

Prostaglandin E 2 Constricts Pressurized Parenchymal Arterioles
Although PGE 2 released from astrocytes has been proposed as a major mediator of neurovascular coupling, whether PGE 2 actually dilates parenchymal arterioles has not been experimentally determined. To test this directly, we assessed the effects of different concentrations of PGE 2 on the diameter of isolated parenchymal arterioles, preconstricted by elevation of intravascular pressure to a physiologic level (40 mm Hg). Surprisingly, rather than inducing dilation, PGE 2 constricted cerebral parenchymal arterioles from rat (Figures 1A and 1B) and mouse ( Figures 1C to  1E ) in a concentration-dependent manner. Prostaglandin E 2 (1 mmol/L) constricted rat and mouse parenchymal arterioles by 18.6 ± 3% (n ¼ 11) and 16.5 ± 2% (n ¼ 21), respectively.
In mouse, vasoconstriction induced by PGE 2 (1 mmol/L) was significantly higher at an intraluminal pressure of 20 mm Hg, than at 80 mm Hg (25.8 ± 2% versus 10.8 ± 1%, n ¼ 7, Supplementary  Figures 1B and C) . Superfusing mouse parenchymal arterioles with aCSF gassed with 5% CO 2 , 10% O 2 , 85% N 2 to lower the oxygen tension had no effect on the constriction to 1 mmol/L PGE 2 . The constriction measured in 10% O 2 (17.1 ± 2.6%, n ¼ 7) was very similar to the above-mentioned value in 20% oxygen. Thus, we have found that PGE 2 invariably constricted parenchymal arterioles over a range of test conditions. Under these same test conditions, NS309, a synthetic activator of endothelial SK and IK channels, always dilated the parenchymal arterioles ( Figures 1A  and 1C ), indicating that their dilator capacity was not impacted by the test conditions employed.
Prostaglandin E 2 -Induced Constriction of Pressurized Parenchymal Arterioles is Mediated by EP 1 Receptors
In studies of newborn and adult pigs, an assessment of PGE 2 receptor subtypes along with measurements of the effects of PGE 2 on IP 3 and cyclic adenosine monophosphate production suggests a predominant expression of EP 1 with lesser levels of EP 3 in adult brain microvessels. 11 In mouse parenchymal arterioles, we found that vasoconstriction to PGE 2 (1 mmol/L) was inhibited by the prostanoid receptor antagonist AH6809 (10 mmol/L), which does not discriminate among EP 1 , EP 2 , and EP 3 receptors ( Figures 1C  and 1D ). 12 SC51322 (1 mmol/L), a selective antagonist of the EP 1 receptor, 12 completely inhibited the constriction to PGE 2 ( Figures  1C and 1D ), indicating that PGE 2 acts through EP 1 receptors to constrict parenchymal arterioles. This is consistent with the likely coupling of EP 1 receptors to G proteins of the G q class, which typically mediate the contractile response to vasoconstrictor agonists. Prostaglandin E 2 did not cause vasodilation in the presence of AH6809 or SC51322.
The Vasodilator Adenylyl Cyclase-Protein Kinase Pathway is Intact in Parenchymal Arterioles
It has been proposed that PGE 2 , acting through G s -coupled receptors (e.g., EP 4 ), stimulates the adenylyl cyclase-PKA pathway to dilate parenchymal arterioles. 8 To confirm that the adenylyl cyclase-PKA pathway is operational in parenchymal arterioles, we tested the effects of the endogenous agents, adenosine and PGI 2 , which have been shown to relax smooth muscle through this mechanism. Both adenosine and prostacyclin caused rapid and reversible dilation of parenchymal arterioles (Figures 1C, 1E, and  1F ). Vasodilation to adenosine was prevented by preincubation with the adenosine A 2A receptor antagonist ZM241385 ( Figure 1D) .
Prostaglandin E 2 Constricts Pressurized Mouse Pial Arterioles
Previous studies have investigated the effects of PGE 2 in isolated cerebral arteries from different species (Supplementary Table 1) , the majority of which have shown vasoconstriction. Arteries from guinea pig, dog, pig, and baboon constrict in response to PGE 2 , whereas feline pial arteries display weak relaxation at lower concentrations and contraction at higher concentrations of PGE 2 . Studies using rat, rabbit, and postmortem human cerebral arteries have reached very divergent conclusions ( Supplementary Table 1 ). In tests of PGE 2 (0.1 and 1 mmol/L) on middle and posterior cerebral arteries from adult mice, we observed only vasoconstriction ( Supplementary Figures 1D and E) .
DISCUSSION
A number of studies have proposed that astrocyte-derived PGE 2 makes a major contribution to functional hyperemia. 8 According to this model, PGE 2 , generated via a Ca 2 þ -dependent mechanism through the action of astrocytic endfoot COX1 on phospholipase A 2 -derived arachidonic acid, is released from astrocytes and activates receptors on vascular smooth muscle cells, presumably G s -coupled EP 4 receptors, to promote arteriolar dilation. Much of the evidence for this mechanism comes from inhibitor-based studies using brain slice preparations in which Ca 2 þ elevation in astrocytes is induced directly through application of a metabotropic glutamate receptor agonist or indirectly through electrical field stimulation of neurons, after which the effects of COX inhibitors on arteriolar dilation are measured. These studies have yielded mixed results. 6, 7 Several neurovascular coupling agents have been proposed including prostaglandins, epoxyeicosatrienoic acids, adenosine, oxygen, nitric oxide, H þ , and K þ . 1, 8 Although mechanisms of functional hyperemia may vary substantially between regions of the brain, one absolute criterion that a putative 'gliotransmitter' must satisfy, if it is to couple neuronal activation to vasodilation, is a demonstrated ability to dilate isolated arterioles. Adenosine, prostacyclin, and external H þ and K þ 4,5,13 are potent vasodilators that induce a rapid dilation when directly applied to isolated arterioles, and therefore fulfill this requirement. Prostaglandin E 2 does not. Although the remote possibility that an unknown vasoconstrictor is released from remnant endfoot membranes in response to PGE 2 cannot be formally excluded, we consider this highly unlikely given that pial arteries, which lack endfeet also constrict to PGE 2 (Supplementary Figures 1D and E) and no dilation was observed in parenchymal arterioles in the presence of an EP 1 blocker (Figure 1) . Therefore, our results clearly indicate that PGE 2 does not dilate cerebral parenchymal arterioles (Figure 1) , which are critical to neurovascular coupling, but instead causes vasoconstriction through activation of EP 1 receptors.
Interpretation of the effects of exogenous application of PGE 2 on arteriolar diameter in brain slices or in vivo is potentially complicated by indirect effects on neurons and astrocytes. Our observations are consistent with studies reporting vasoconstriction of cerebral arteries in vivo 14, 15 and reduced cerebral blood flow 16, 17 in response to PGE 2 . Nevertheless, application of PGE 2 has been shown to dilate cerebral arteries 18, 19 and parenchymal arterioles in vivo, 3 and in neonatal brain slices. 7 The latter finding could be explained by the observation that EP 2 and EP 4 receptors, which mediate vasodilatory pathways, are predominantly expressed in the early stage of life. 11, 20, 21 In the adult animal, it has been shown that trigeminal neurons, which innervate pial arteries, release the vasorelaxant calcitonin gene-related peptide in response to PGE 2 . 22, 23 Depending on experimental conditions, perivascular nerves may or may not be functional-a possible cause of the discrepancies in both in vitro (Supplementary Table 1 ) and in vivo studies noted above. It should also be borne in mind that other studies have indicated a role for COX2 and PGE 2 in modulating synaptic signaling in neurons. 24, 25 Because astrocytes are recruited by synaptic release of glutamate, 1 inhibition of such a mechanism would decrease neurovascular coupling efficiency, a result that could mistakenly be taken as evidence for a direct neurovascular-coupling function of PGE 2 . This hypothesis is consistent with the demonstrated contribution of COX2 to functional hyperemia 9 despite the absence of COX2 expression in astrocytes. 10 Moreover, ablation of the Cox1 gene in mice does not affect functional hyperemia, 26 ruling out a contribution of this isoform to PGE 2 production in this context. Accordingly, rather than providing evidence for a role for PGE 2 as an astrocyte-derived agent, the effects of PGE 2 or COX inhibitors in brain slices or in vivo 3,7 may reveal their actions in neurons and synaptic transmission. 9, 27 In fact, it is possible that activation of cerebral arteriolar EP 1 receptors and subsequent vasoconstriction may contribute to the neurotoxicity of PGE 2 . 27 In conclusion, our results provide strong evidence that PGE 2 is not directly involved in neurovascular coupling, and underscore the need to directly test putative neurovascular coupling transmitters on their target arterioles.
